C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026)

C4 Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $27.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 33.25% year-over-year to $27.2 million in Q1 2026; TTM through Mar 2026 was $27.2 million, a 33.25% decrease from a year earlier, with the FY2025 full-year figure at $33.0 million, down 26.88% from the prior year.
• Total Current Liabilities fell to $27.2 million in Q1 2026 per CCCC's latest filing, from $33.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $55.0 million in Q1 2024 and bottomed at $27.2 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $44.5 million (2025), against an average of $42.5 million.
• Across the five-year window, Total Current Liabilities jumped 43.02% in 2024 and slumped 33.25% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $44.5 million in 2022, then fell by 4.0% to $42.8 million in 2023, then increased by 5.64% to $45.2 million in 2024, then retreated by 26.88% to $33.0 million in 2025, then dropped by 17.51% to $27.2 million in 2026.
• Per Business Quant, the three latest CCCC Total Current Liabilities figures stand at $27.2 million (Q1 2026), $33.0 million (Q4 2025), and $35.9 million (Q3 2025).